췌장암 환자의 보조요법의 항암 치료제 결정을 위한 접근
Selection of Optimal Adjuvant Chemotherapeutic Agents for Pancreatic Cancer Treatment
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Pancreatic cancer generally has a dismal prognosis, with a 5-year overall survival rate of approximately 10%. At present, surgical resection is the only treatment with a curative aim; however, it is applicable to only 15–20% patients with pancreatic cancer at the time of diagnosis and the median survival following treatment with surgery alone is only 11–20 months. Many trials have shown that adjuvant chemotherapy offers improved outcomes over observation following surgical resection. Recently, modified folinic acid–fluorouracil–irinotecan–oxaliplatin (FOLFIRINOX) treatment following surgical resection in patients with good performance status has shown an impressive 9-month increase in disease-free survival. However, patients included in the study were selected based on a narrow set of criteria, and adverse events during adjuvant chemotherapy remain a limitation. In this article, we review some key trials of adjuvant chemotherapy treatment for pancreatic cancer and discuss future perspectives including neoadjuvant treatment approaches.
Abstract
Pancreatic cancer generally has a dismal prognosis, with a 5-year overall survival rate of approximately 10%. At present, surgical resection is the only treatment with a curative aim; however, it is applicable to only 15–20% patients with pancreatic cancer at the time of diagnosis and the median survival following treatment with surgery alone is only 11–20 months. Many trials have shown that adjuvant chemotherapy offers improved outcomes over observation following surgical resection. Recently, modified folinic acid–fluorouracil–irinotecan–oxaliplatin (FOLFIRINOX) treatment following surgical resection in patients with good performance status has shown an impressive 9-month increase in disease-free survival. However, patients included in the study were selected based on a narrow set of criteria, and adverse events during adjuvant chemotherapy remain a limitation. In this article, we review some key trials of adjuvant chemotherapy treatment for pancreatic cancer and discuss future perspectives including neoadjuvant treatment approaches.
참고문헌 (19)
- Siegel RL, "Cancer statistics, 2019", CA Cancer J Clin, 69, pp.7~34 (2019)
- Neoptolemos JP, "Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer(ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial", Lancet, 389, pp.1011~1024 (2017)
- Oettle H, "Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001randomized trial", JAMA, 310, pp.1473~1481 (2013)
- Neoptolemos JP, "A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer", N Engl J Med, 350, pp.1200~1210 (2004)
- Siegel RL, "Cancer statistics, 2020", CA Cancer J Clin, 70, pp.7~30 (2020)
- Conroy T, "FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer", N Engl J Med, 379, pp.2395~2406 (2018)
- Conroy T, "FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer", N Engl J Med, 364, pp.1817~1825 (2011)
- Silvestris N, "Clinical practice guidelines for diagnosis, treatment and follow-up of exocrine pancreatic ductal adenocarcinoma: evidence evaluation and recommendations by the italian association of medical oncology (AIOM)", Cancers (Basel), 12, pp.1681~ (2020)
- Tempero MA, "APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P", G) vs gemcitabine (G)for surgically resected pancreatic adenocarcinoma, 2019, pp.37(suppl 15), 4000~
- Khorana AA, "Potentially curable pancreatic adenocarcinoma : ASCO clinical practice guideline update", J Clin Oncol, 37, pp.2082~2088 (2019)
- Sohal D, "SWOG S1505 : results of perioperative chemotherapy(peri-op CTx)with mfolfirinox versus gemcitabine", nab-paclitaxel(Gem, J Clin Oncol, pp.2020[DOI]
- Ma SJ, "Association of timing of adjuvant therapy with survival in patients with resected stage I to II pancreatic cancer", JAMA Netw Open, 2, pp.e199126~ (2019)
- Valle JW, "Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas : ongoing lessons from the ESPAC-3 study", J Clin Oncol, 32, pp.504~512 (2014)
- Berglund A, "Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?", Ann Oncol, 19, pp.400~402 (2008)
- Lohrisch C, "Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer", J Clin Oncol, 24, pp.4888~4894 (2006)
- Kim HW, "Early versus delayed initiation of adjuvant treatment for pancreatic cancer", PLoS One, 12, pp.e0173960~ (2017)
- Domínguez-Muñoz JE, "Pancreatic enzyme therapy for pancreatic exocrine insufficiency", Curr Gastroenterol Rep, 9, pp.116~122 (2007)
- Boyd AD, "Screening for depression, sleep-related disturbances, and anxiety in patients with adenocarcinoma of the pancreas : a preliminary study", ScientificWorldJournal, 2012, pp.650707~ (2012)
- Turaga KK, "Suicide in patients with pancreatic cancer", Cancer, 117, pp.642~647 (2011)